Literature DB >> 10759855

Aprotinin binding to amyloid fibrils.

I Cardoso1, P J Pereira, A M Damas, M J Saraiva.   

Abstract

Different low molecular mass ligands have been used to identify amyloid deposits. Among these markers, the dyes Thioflavin T and Congo Red interact specifically with the beta-sheet structure arranged in a cross-beta conformation, which is characteristic of amyloid. However, the molecular details of this interaction remain unknown. When labelled with technetium-99m, the proteinase inhibitor aprotinin has been shown to represent a very important radiopharmaceutical agent for in vivo imaging of extra-abdominal deposition of amyloid in amyloidosis of the immunoglobulin type. However, no information is available as to whether aprotinin binds other types of amyloid fibrils and on the nature and characteristics of the interaction. The present work shows aprotinin binding to insulin, transthyretin, beta-amyloid peptide and immunoglobulin synthetic amyloid fibrils by a specific dot-blot ligand-binding assay. Aprotinin did not bind amorphous precipitates and/or the soluble fibril precursors. A Ka of 2.9 microM-1 for the binding of aprotinin to insulin amyloid fibrils was determined by Scatchard analysis. In competition experiments, analogues such as an aprotinin variant, a spermadhesin and the soybean trypsin inhibitor were tested and results suggest that both aprotinin and the spermadhesin interact with amyloid fibrils through pairing of beta-sheets of the ligands with exposed structures of the same type at the surface of amyloid deposits. An electrostatic component may also be involved in the binding of aprotinin to amyloid fibrils because important differences in binding constants are observed when substitutions V15L17E52 are introduced in aprotinin; on the other hand beta-sheet containing acidic proteins, such as the soybean trypsin inhibitor, are unable to bind amyloid fibrils.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759855     DOI: 10.1046/j.1432-1327.2000.01237.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Time for new imaging and therapeutic approaches in cardiac amyloidosis.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Walter Noordzij; Johan Bijzet; Bouke P C Hazenberg; Hans L A Nienhuis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-23       Impact factor: 9.236

Review 2.  Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).

Authors:  Yukio Ando
Journal:  Med Mol Morphol       Date:  2005-09       Impact factor: 2.309

Review 3.  A Narrative Review of 99mTc-Aprotinin in the Diagnosis of Cardiac Amyloidosis and a New Life for an Unfairly Abandoned Drug.

Authors:  Carlo Aprile; Lorenzo Lodola
Journal:  Biomedicines       Date:  2022-06-10

4.  Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts.

Authors:  Emily B Martin; Angela Williams; Eric Heidel; Sallie Macy; Stephen J Kennel; Jonathan S Wall
Journal:  Biochem Biophys Res Commun       Date:  2013-05-23       Impact factor: 3.575

5.  Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity.

Authors:  Ana Frangolho; Bruno E Correia; Daniela C Vaz; Zaida L Almeida; Rui M M Brito
Journal:  Molecules       Date:  2020-12-03       Impact factor: 4.411

6.  Searching for the Best Transthyretin Aggregation Protocol to Study Amyloid Fibril Disruption.

Authors:  Elisabete Ferreira; Zaida L Almeida; Pedro F Cruz; Marta Silva E Sousa; Paula Veríssimo; Rui M M Brito
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.